ARMO BioSciences Appoints Herb Cross as Chief Financial Officer

REDWOOD CITY, Calif., Nov. 28, 2017 /PRNewswire/ -- ARMO BioSciences, Inc., a late-stage immuno-oncology company, today announced the appointment of Herb Cross as Chief Financial Officer, a newly-created position. Mr. Cross has over twenty years of experience, with executive leadership roles in both private and public biotechnology companies.

"Herb is a strong financial executive with significant experience in life sciences companies during periods of rapid growth and late-stage clinical execution," said Peter Van Vlasselaer, Ph.D., President and Chief Executive Officer of ARMO BioSciences.  "As we advance AM0010 and our pipeline, Herb's broad experience leading finance and corporate strategy will contribute significantly to the execution of our plans. With Herb's appointment, we have continued to build out a highly-experienced and results-oriented leadership team to execute on our strong pipeline of assets here at ARMO BioSciences."

"ARMO's novel immuno-oncology therapies have tremendous promise, and I am very excited to join Peter and the team as we continue to refine the corporate strategy and advance the pipeline," said Herb Cross, Chief Financial Officer of ARMO BioSciences.

Mr. Cross has over twenty years of experience leading finance functions at both private and public companies and working with a major public accounting firm. Before joining ARMO BioSciences, Mr. Cross was the Chief Financial Officer at Balance Therapeutics, Inc., where he led the finance, investor relations, information technology, and other administrative functions. Previously, Mr. Cross was Chief Financial Officer and interim Chief Executive Officer at KaloBios Pharmaceuticals, where he was responsible for overall strategic leadership and led the finance and administrative functions. Mr. Cross also served as Chief Financial Officer at Affymax. Earlier in his career, Mr. Cross was Vice President, Finance at Facet Biotech Corporation, a spin-off of PDL BioPharma, where he was Executive Director, Finance and Corporate Controller. He began his career at Arthur Andersen, LLP.

Mr. Cross received a Bachelor of Science in Business Administration from the Haas School of Business at the University of California, Berkeley. He is a certified public accountant, currently inactive, in the state of California.

About ARMO BioSciences
ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary products that activate the immune system of cancer patients to recognize and eradicate tumors. The Company's lead product candidate, AM0010 (pegilodecakin, PEGylated Interleukin-10), stimulates the survival, expansion and killing (cytotoxic) potential of a particular type of white blood cell in the immune system called CD8+ T cells.  CD8+ T cells recognize and kill cancer cells and an increased presence of intra-tumoral CD8+ T cells may result in improved prognosis and survival in patients.

In addition, ARMO is developing a robust immuno-oncology pipeline that includes validated product candidates such as an anti-PD-1 monoclonal antibody, aimed at treating a variety of cancers in combination with standard of care treatments and emerging immunotherapies.

For more information, please visit www.armobio.com.

SOURCE ARMO BioSciences, Inc.

Related Links

http://www.armobio.com